Genome Editing Market to Hit $21.36 Billion by 2030, With a CAGR of 17.33% Asserts Strategic Market Research

According to Strategic Market Research, the Global Genome Editing Market Size is Expected to Grow from $5.06 Billion in 2021 to $21.36 Billion by 2030 at CAGR of 17.33% During the Forecast Period; Technological Advancement Coupled with CRISPER/Cas9 Technology is Poised to Drive the Industry Growth.

New York, USA, Sept. 12, 2022 (GLOBE NEWSWIRE) -- The Global Genome Editing Market was USD 5.06 Billion in 2021 and will reach USD 21.36 Billion in 2030 at a 17.33% CAGR. Genome editing, also known as genome engineering or gene editing, is the method that involves altering genetic materials in an organism's DNA in order to monitor changes and enhance understanding of diseases and conditions caused by genetic defects, such as cystic fibrosis (CF), single nucleotide polymorphisms (SNPs), sickle cell disease, and hemophilia. The main objective of genome editing is to find ways to treat diseases, increase the effectiveness of Endogenous gene labeling, embryo genome editing, enhance plant health, Targeted transgene addition, and prevent endemic diseases like malaria and diarrhea.

To get a first-hand overview of the report, Request a Sample at

Genome Editing Market Insights: 

  • The consumables and reagent segment had the biggest market share based on products and services.
  • Based on technology, the CRISPR segment dominated the Genome Editing Market.
  • The cell line engineering segment ruled the market with a maximum share by application.
  • The biotechnology and pharmaceutical companies shared a dominant position in the market based on end-user.
  • Regionally, North America held a significant position in the genome editing market.

Factors influencing the Genome Editing Market growth

Factors like increased incidence of genetic disorders (i.e., increased investment in the sector and single-gene disorders) are boosting its growth rate. 

  • A genetic disorder occurs when a mutation (also known as a pathogenic variant) affects the genes or when a person has an insufficient amount of genetic material. According to the US Genetic and Rare Disease Information Center, nearly thirty million Americans, or one in ten, have a genetic or rare disease. According to data from a WHO report, a congenital abnormality or genetic defect is found in about 2-5% of all newborns. These births influence about 30% of hospital admissions to pediatric wards. Congenital malformations are among the primary causes of infant mortality in Bahrain, Qatar, Kuwait, and Oman, according to the WHO, and they are the main cause of infant mortality in the United Arab Emirates. With the increasing incidence of genetic disorders globally, the need for solutions based on genome editing and drug development is also increasing.

  • With the development of CRISPR technology, investments in the sector have experienced rapid growth. In 2021, the genome editing sector raised more than USD 1.3 billion in investments, with 18 deals including CRISPR technology. The Mammoth Bioscience companies received the most funding to enhance their facilities and technologies to create the future CRISPR technology. As a result of firms' increasing investments in enhancing current technologies, the genome editing market is likely to expand rapidly.

Genome Editing Market: A thorough Segmentation Analysis

The worldwide Genome Editing Market segmentation has been performed based on Product and Service, Technology, Application, End-user & Geography. 

By Product and Service:

  • Systems
  • Software
  • Services
  • Reagents
  • Consumables

By Technology

  • ZFN
  • Antisense
  • Other Technologies

By Application

  • Animal Genetic Engineering
  • Plant Genetic Engineering
  • Drug Discovery and Development
  • Diagnostic applications
  • Cell Line Engineering
  • Other Applications

By End-user

  • Pharmaceutical companies
  • Government Research Institutes
  • Biotechnology companies
  • Academic Research Institutes

For Geography
North America

  • USA
  • Mexico
  • Canada
  • Rest of North-America


  • Australia
  • India
  • Japan
  • Vietnam
  • China
  • South Korea
  • Rest of APAC

Europe Continent

  • Germany
  • France
  • Italy
  • United Kingdom
  • Spain
  • The rest of Europe 


  • Saudi Arab
  • Brazil
  • Qatar
  • Argentina
  • South Africa
  • Nigeria
  • UAE
  • Rest of LAMEA

Make a Direct Purchase of the latest Genome Editing Market Report published in the month of Aug-2022. Click the below link to initiate the purchase:

The consumables and reagent segment had the biggest market share based on products and services due to the high sales volume they generated from their widespread use in the industry. Brefeldin A, azidothymidine, nocodazole, and abscisic acid are commonly used reagents in labs and institutes with genetic engineering facilities. Reagents and consumables will be used more frequently as more labs, hospitals, and academic institutions will further support the market's expansion.

Based on technology, the CRISPR segment dominated the Genome Editing Market. It is primarily due to its increased application in healthcare, biotechnology, and agriculture. Research is being done on CRISPR/Cas9 to find cures for serious illnesses like the human immunodeficiency virus and Huntington's disease (HIV). According to research, Huntington's illness is caused by a mutant protein, and with the Use of CRISPR/Cas9 in mouse models, the development of the mutant protein was reduced by about 90%. According to studies, CRISPR/Cas9 has also been successfully used to eliminate the viral infection-causing receptors. With several hundred experiments and studies being performed worldwide using CRISPR techniques, this technology is expected to maintain its dominance in the segment.

Based on application, cell line engineering ruled the market with the maximum share. It is primarily due to its extensive application in agriculture, pharmacology, biology, and other fields. Cell line engineering is creating clusters of cells from a specific tissue type (such as a specific organ or a plant's xylem) to maintain consistency in the resulting tissue. Cell lines have been commonly applied in drug development, protein synthesis, artificial tissue generation, and vaccine development. Over 36,000 cell lines have been developed for use in academia, healthcare, and pharmacogenomics due to extensive research in the field. Therefore, with numerous research opportunities available using cell lines, the market is expected to experience sustained growth in the coming years.

The biotechnology and pharmaceutical companies shared a dominant position in the market based on end-user. Both companies are using gene editing to generate innovative therapeutics in the healthcare industry. Additionally, gene editing is used by biotech companies to produce GM seeds and transgenic animals. After a ten-year trial period, China recently approved the use of four GM corn varieties and three GM soybean varieties. Over 21% of Australia's canola is grown with GM seeds. With increased research in the field due to company investments, biotech and pharmaceutical companies will remain dominant in the end-user segment.

Regionally, North America leads the genome editing market owing to numerous R&D centers and headquarters for pharmaceutical and biotech companies.
Additionally, the agriculture and healthcare infrastructures, which are quickly adopting new technologies, help the region sustain its dominant position. According to records, over 2,000 pharmaceutical companies and 6,600 registered biotechnology companies are in the US. More than 50 well-known pharmaceutical companies and more than 1,000 registered biotechnology companies are in Canada. As a result of policies that promote business growth, the number of pharmaceutical and biotechnology companies in the region will continue to grow, boosting overall regional growth.

Key players prevailing in Genome Editing Market:

  • Beren Therapeutics
  • Agilent Technologies
  • Creative Biogene
  • Intellia Therapeutics
  • Lonza
  • Horizon Discovery Group plc.
  • Tecan Life-Sciences
  • Thermo Fisher-Scientific
  • Synthego
  • Integrated DNA Technologie
  • Bean Therapeutics
  • Bluebird Bio
  • Others

Before initiating a purchase, make a Pre-order enquiry and get a detailed overview of the content of the report.


Report CoverageDetails
Forecast Period2021-2030
Forecast Period 2021 to 2030 CAGRCAGR of 17.33%
2030 Value Projection$ 21.36 billion
Base Year2020
Market Size in 2021$5.06 billion
Historical Data for2015-2019
No. of Pages135
CompaniesAgilent Technologies, Beam Therapeutics, Beren Therapeutics, Bluebird Bio, Caribou Biosciences, Inc., Cellectis S.A, Creative Biogene, CRISPR Therapeutics AG, Editas Medicine, Eurofins Scientific, GenScript, Horizon Discovery Group plc., Integrated DNA Technologies, Inc., Intellia Therapeutics, Inc., Lonza, Merck KGaA, New England Biolabs, OriGene Technologies, PerkinElmer, Precision Biosciences, Recombinetics, Regeneron Pharmaceuticals, Sangamo Therapeutics, Inc., Synthego, Tecan Life Sciences, Thermo Fisher Scientific Inc., Transposagen Biopharmaceuticals, and Vigene Biosciences.
Leading Segment Based on technologyCRISPR
 Leading Region North America

To read the summary of the report, visit the website at

Recent Developments

  •  The University of California research team discovered a new method to "repair" genetic flaws in July 2022. The scientists developed red-eye colour in fruit flies by targeting only a single strand of DNA with "soft" CRISPR. Their goal is to conduct additional research to make it feasible to treat and cure human genetic diseases.

  • Scientists at the Indiana Center for Regenerative Medicine and Engineering created A technology that can regenerate tissue in a live body in July 2022. Tissue Nano Transfection (TNT) was created using gene editing technology to treat crushed nerves, injured legs, diabetic retinopathy, and stroke brains.

  • In a study published in July 2022, Nothobranchius furzeri (N. furzeri), also known as the African turquoise killifish, was discovered to be a useful organism for studying vertebral aging. The fish were genetically modified using the gene knockout method to make them more suitable for aging and embryonic diapause studies. These techniques shorten the length of the experiment and speed up gene identification.

Related Reports

Drug Delivery Devices Market
The Drug Delivery Devices Market report gives detailed insights on restraining factors, opportunities, challenges, etc. The Drug Delivery Devices Market was worth USD 239.2 Billion in 2021, and by 2030 it will reach USD 340.45 Billion with a 7.1% CAGR. An increasing occurrence of chronic and acute disorders, improved government support, and increased R&D spending are accelerating its growth rate. Major companies in this market are Becton Dickinson, 3M, F. Hoffmann-La Roche, Gene Tech Company Ltd., Novartis AG, etc.

Injectable Drug Delivery Market
SMR's Injectable Drug Delivery Market Report explains its opportunities, restraints, growth factors, etc. The Injectable Drug Delivery Market in 2021 was USD 615.87 Billion, and by 2030, it will be worth USD 1677.91 Billion with an 11.78% CAGR. The increase in the number of needle injuries, chronic diseases, and usage of injections worldwide is accelerating its growth rate. Organizations playing a pivotal role in this market are Pfizer Inc., B. Braun Melsungen, Teva Pharmaceuticals Industries Ltd., Schott AG, etc.

Lateral Flow Assays Market
The Lateral Flow Assays Market Report by SMR explains its variety of challenges, driving factors, restraints, etc. The Lateral Flow Assays Market value was worth USD 8.76 Billion in 2021, and it will be worth USD 12.85 Billion in 2030, with a 4.34% CAGR. Factors accelerating the market growth rate are the rapidly increasing geriatric population, high incidence of infectious disease globally, rising demand for POC devices, Increasing use of home-based lateral flow assay devices, and the need for rapid diagnostic testing for COVID-19. Companies operating in this market are Siemens AG, Danaher Corporation, Abbott Laboratories, Quidel Corporation, etc.

Oncology Drugs Market
The Oncology Drugs Market Report by SMR outlines its challenges, opportunities, restraints, etc. The Oncology Drugs Market value in 2021 was USD 177.54 Billion and will reach USD 474.06 Billion by 2030, representing a CAGR of 11.53%. Factors boosting the growth rate are increased use of tobacco, advancement in treatment types, and an increasing number of cancer cases. This market includes Bayer AG, Johnson & Johnson, Pfizer Inc., Novartis International AG, AbbVie, Astellas Pharma Inc., etc.

Organ Preservation Market
SMR's Organ Preservation Market Report delivers a clear-cut concept regarding its opportunities, growth factors, restraints, etc. The Organ Preservation Market value was USD 206.89 Billion in 2021 and will be worth USD 377.97 Billion in 2030 at a 6.93% CAGR. The growth in cases of multiple organ failure and the growing geriatric population. Organizations playing a pivotal role in this market are Global Transplant Solutions, Vascular Perfusion Solutions, Transplant Biomedicals, Paragonix Technologies, 21st Century Medicine, Biochefa, etc.

About Us:
Strategic Market Research facilitates organizations globally in taking pivotal business decisions by furnishing Syndicated and Customized Research Reports, which are highly precise in terms of market numbers. We believe that every firm, whether it is a startup in the Introduction stage of the Product Life cycle or an established one at the growth stage, requires market research services to streamline its key business blueprint. It may be related to Product Launch, Go to Market strategies, Competitive Analysis, or new geographical penetration and expansion.

Contact Us:
Strategic Market Research LLP.
Sunil Kumar 
India: +91-8260836500
Press Release:

Connect Us: